Analytical Data
-
基因名
EG-VEGF
- Application
-
别名
EG-VEGF；Prokineticin-1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P58294
-
表达区间
20-105aa
-
氨基酸序列
AVITGACERDVQCGAGTCCAISLWLRGLRMCTPLGREGEECHPGSHKVPF FRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF
-
分子量
10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Endothelial growth factor B (EG-VEGF) is a recently identified member of the vascular endothelial growth factor family, specifically linked to the regulation of lymphangiogenesis and angiogenesis. As a crucial player in the development and maintenance of lymphatic endothelial cells, EG-VEGF has drawn considerable attention in the fields of immunology and oncology. Its expression is significantly upregulated in various pathological conditions, including tumors and inflammatory diseases, suggesting its role in promoting lymphatic vascular growth and remodeling. Research indicates that EG-VEGF might contribute to tumor metastasis through the facilitation of lymphatic invasion, making it a potential biomarker for tumor progression and a target for therapeutic interventions. The recombinant protein form of EG-VEGF has been studied for its functional characteristics in modulating lymphatic endothelial cell proliferation, migration, and survival. Understanding the molecular mechanisms and signaling pathways involved in EG-VEGF activity could lead to novel strategies for treating diseases characterized by abnormal lymphatic function, such as cancer and lymphedema. Overall, the study of EG-VEGF recombinant protein offers promising avenues for both basic research and clinical applications in vascular biology.
